Gefitinib

Across CCLE and GDSC cell-line panels, response to Gefitinib is significantly associated with the mutation status of multiple genes, with KIDNEY cell lines showing a particularly strong set of associations.

The most reproducible Gefitinib response-associated genes across cancer lineages are TP53, TSHZ3, and AHNAK2, each associated with drug response in up to 3 lineages. Since the analysis identifies associations rather than directional relationships, both response-to-biomarker and biomarker-to-response views are provided.

Each biomarker is linked to its corresponding Q-omics profile. The box plot shows the strongest observed association, Gefitinib response grouped by TP53 status in KIDNEY.

Mutation status biomarkers of Gefitinib response

Ranked by combined sampling and lineage consensus. X-score (response→biomarker) and Y-score (biomarker→response) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner gene	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
KIDNEY	TP53 →	-2.459	-0.584	.003	<.001	2	3
LUNG_NSCLC_LUAD	TSHZ3 →	-1.485	-0.454	.025	.035	3	2
BREAST	AHNAK2 →	+3.169	+0.423	.010	.031	3	2
OVARY	GPATCH8 →	+2.877	+0.724	.020	<.001	3	2
BLOOD_Lymphoma	FAT1 →	-2.069	-0.201	.008	.027	3	2
SKIN	COL22A1 →	-3.169	-0.300	.011	.012	3	2

Each biomarker links to its Q-omics profile. Showing the 6 strongest associations by consensus.

Gefitinib response by TP53 status — KIDNEY

Explore this box plot interactively →